These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10189254)

  • 1. Development of a single-shot subunit vaccine for HIV-1. 5. programmable in vivo autoboost and long lasting neutralizing response.
    Cleland JL; Lim A; Daugherty A; Barron L; Desjardin N; Duenas ET; Eastman DJ; Vennari JC; Wrin T; Berman P; Murthy KK; Powell MF
    J Pharm Sci; 1998 Dec; 87(12):1489-95. PubMed ID: 10189254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a single-shot subunit vaccine for HIV-1.
    Cleland JL; Powell MF; Lim A; Barrón L; Berman PW; Eastman DJ; Nunberg JH; Wrin T; Vennari JC
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S21-6. PubMed ID: 7865303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a single-shot subunit vaccine for HIV-1. 2. Defining optimal autoboost characteristics to maximize the humoral immune response.
    Cleland JL; Barrón L; Berman PW; Daugherty A; Gregory T; Lim A; Vennari J; Wrin T; Powell MF
    J Pharm Sci; 1996 Dec; 85(12):1346-9. PubMed ID: 8961151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons .
    Powell MF; Cleland JL; Eastman DJ; Lim A; Murthy K; Newman MJ; Nunberg JH; Weissburg RP; Vennari JC; Wrin T
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S105-8. PubMed ID: 7865282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea pigs.
    Powell MF; Eastman DJ; Lim A; Lucas C; Peterson M; Vennari J; Weissburg RP; Wrin T; Kensil CR; Newman MJ
    AIDS Res Hum Retroviruses; 1995 Feb; 11(2):203-9. PubMed ID: 7742035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.
    Newman MJ; Wu JY; Gardner BH; Anderson CA; Kensil CR; Recchia J; Coughlin RT; Powell MF
    Vaccine; 1997 Jun; 15(9):1001-7. PubMed ID: 9261947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein 120 of HIV-1.
    Anderson KP; Lucas C; Hanson CV; Londe HF; Izu A; Gregory T; Ammann A; Berman PW; Eichberg JW
    J Infect Dis; 1989 Dec; 160(6):960-9. PubMed ID: 2555423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres.
    Shi L; Caulfield MJ; Chern RT; Wilson RA; Sanyal G; Volkin DB
    J Pharm Sci; 2002 Apr; 91(4):1019-35. PubMed ID: 11948541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120.
    Cleland JL; Barrón L; Daugherty A; Eastman D; Kensil C; Lim A; Weissburg RP; Wrin T; Vennari J; Powell MF
    J Pharm Sci; 1996 Dec; 85(12):1350-7. PubMed ID: 8961152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biodegradable microspheres containing influenza A vaccine: immune response in mice.
    Hilbert AK; Fritzsche U; Kissel T
    Vaccine; 1999 Mar; 17(9-10):1065-73. PubMed ID: 10195616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons.
    Haigwood NL; Nara PL; Brooks E; Van Nest GA; Ott G; Higgins KW; Dunlop N; Scandella CJ; Eichberg JW; Steimer KS
    J Virol; 1992 Jan; 66(1):172-82. PubMed ID: 1727480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic local tissue reactions, long-term immunogenicity and immunologic priming of mice and guinea pigs to tetanus toxoid encapsulated in biodegradable polymer microspheres composed of poly lactide-co-glycolide polymers.
    Gupta RK; Alroy J; Alonso MJ; Langer R; Siber GR
    Vaccine; 1997 Nov; 15(16):1716-23. PubMed ID: 9364673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.
    Connor RI; Korber BT; Graham BS; Hahn BH; Ho DD; Walker BD; Neumann AU; Vermund SH; Mestecky J; Jackson S; Fenamore E; Cao Y; Gao F; Kalams S; Kunstman KJ; McDonald D; McWilliams N; Trkola A; Moore JP; Wolinsky SM
    J Virol; 1998 Feb; 72(2):1552-76. PubMed ID: 9445059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies.
    Smith DH; Winters-Digiacinto P; Mitiku M; O'Rourke S; Sinangil F; Wrin T; Montefiori DC; Berman PW
    PLoS One; 2010 Aug; 5(8):e12076. PubMed ID: 20711452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins.
    Liao HX; Alam SM; Mascola JR; Robinson J; Ma B; Montefiori DC; Rhein M; Sutherland LL; Scearce R; Haynes BF
    J Virol; 2004 May; 78(10):5270-8. PubMed ID: 15113908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.
    Verschoor EJ; Mooij P; Oostermeijer H; van der Kolk M; ten Haaft P; Verstrepen B; Sun Y; Morein B; Akerblom L; Fuller DH; Barnett SW; Heeney JL
    J Virol; 1999 Apr; 73(4):3292-300. PubMed ID: 10074183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
    AIDS Vaccine Evaluation Group 022 Protocol Team
    J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.
    Graham BS; Keefer MC; McElrath MJ; Gorse GJ; Schwartz DH; Weinhold K; Matthews TJ; Esterlitz JR; Sinangil F; Fast PE
    Ann Intern Med; 1996 Aug; 125(4):270-9. PubMed ID: 8678389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.